AstraZeneca's Imfinzi fails to improve OS in head and neck cancer trial - Pharmaceutical Business Review

AstraZeneca's Imfinzi fails to improve OS in head and neck cancer trial  Pharmaceutical Business Review

AstraZeneca's Imfinzi monotherapy and the combination of Imfinzi and tremelimumab has failed to improve OS rate compared to SoC chemotherapy in head and ...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2RPxroT